KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EBIT (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of EBIT data on record, last reported at $879.9 million in Q4 2025.

  • For Q4 2025, EBIT fell 11.14% year-over-year to $879.9 million; the TTM value through Dec 2025 reached $3.6 billion, down 10.34%, while the annual FY2025 figure was $3.6 billion, 10.34% down from the prior year.
  • EBIT reached $879.9 million in Q4 2025 per REGN's latest filing, down from $1.0 billion in the prior quarter.
  • Across five years, EBIT topped out at $3.3 billion in Q2 2021 and bottomed at $591.7 million in Q1 2025.
  • Average EBIT over 5 years is $1.2 billion, with a median of $1.1 billion recorded in 2025.
  • Peak YoY movement for EBIT: surged 409.93% in 2021, then crashed 66.84% in 2022.
  • A 5-year view of EBIT shows it stood at $1.8 billion in 2021, then plummeted by 37.92% to $1.1 billion in 2022, then dropped by 15.16% to $972.9 million in 2023, then rose by 1.78% to $990.2 million in 2024, then fell by 11.14% to $879.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were $879.9 million in Q4 2025, $1.0 billion in Q3 2025, and $1.1 billion in Q2 2025.